<PAGE>
                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

                    QUARTERLY REPORT FOR THE QUARTERLY PERIOD
                              ENDED MARCH 31, 2002

                           COMMISSION FILE NO. 0-28077

                                 GENELINK, INC.
                 (Name of Small Business Issuer in its charter)

              PENNSYLVANIA                                23-2795613
     (State or other jurisdiction of                  (I.R.S. Employer
       incorporation or organization)                 Identification No.)


         100 S. Thurlow Street
          Margate, New Jersey                              08402
 (Address of principal executive offices)                (Zip Code)

                    ISSUER'S TELEPHONE NUMBER: (609) 823-6991


         Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]

         APPLICABLE ONLY TO CORPORATE ISSUERS: Indicate the number of shares
outstanding of each of the issuer's classes of common stock, as of the latest
practicable date.

         Number of Shares of Common Stock
         Outstanding on May 7, 2002                  17,628,410

Transitional Small Business Disclosure Format        Yes [ ] No [X]


<PAGE>


                                 GENELINK, INC.


PART I.  FINANCIAL INFORMATION

ITEM 1.  Financial Statements.

         Balance Sheets at March 31, 2002 (unaudited) and December 31, 2001

         Statements of Operations for the three months ended March 31, 2002 and
         2001 (unaudited)

         Statements of Cash Flows for the three months ended March 31, 2002 and
         2001 (unaudited)

         Notes to Financial Statements (unaudited)

    The accompanying notes are an integral part of the financial statements.


                                       -2-


<PAGE>


                                                                  GENELINK, INC.
                                                                  BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                                (Unaudited)
                                                                                 March 31,     December 31,
                                                                                   2002            2001
                                                                                -----------    -----------
<S>                                                                            <C>             <C>
ASSETS
  Cash                                                                          $   274,533    $   121,434
  Accounts receivable                                                                 3,971          1,448
  Inventory                                                                           9,366         10,089
  Prepaid expenses                                                                  133,263        152,878
                                                                                -----------    -----------
         Total current assets                                                       421,133        285,849

  Property and equipment                                                             57,523         55,662
  Other assets                                                                       23,460         23,881
                                                                                -----------    -----------
                                                                                $   502,116    $   365,392
                                                                                -----------    -----------
LIABILITIES

  Accounts payable & accrued expenses                                           $   124,087    $    88,816
  Accrued payroll taxes                                                               1,913         11,593
                                                                                -----------    -----------
         Total current liabilities                                                  126,000        100,409

  Accrued compensation                                                              423,525        357,807
  Loans payable-affiliates                                                           58,000         58,000
                                                                                -----------    -----------
                                                                                    607,525        516,216
                                                                                -----------    -----------
STOCKHOLDERS' EQUITY (DEFICIT)
  Common stock, $.01 par value, 75,000,000
    shares authorized 17,509,590 and 16,801,590 shares issued, 17,313,410 and
    16,705,410 outstanding as of March 31, 2002 and December 31, 2001,
    respectively                                                                    175,095        168,015
  Treasury stock, 196,180 and 96,180 shares as of March 31, 2002 and
    December 31, 2001, respectively                                                (205,860)      (109,860)
  Additional paid in capital                                                      5,577,594      5,279,271
  Stock subscriptions receivable                                                 (1,001,312)      (920,189)
  Stock warrants                                                                    458,574        350,334
  Deferred compensation                                                                   0       (200,000)
  Accumulated deficit                                                            (5,109,500)    (4,718,395)
                                                                                -----------    -----------
                                                                                   (105,409)      (150,824)
                                                                                -----------    -----------
                                                                                $   502,116    $   365,392
                                                                                -----------    -----------
</TABLE>

    The accompanying notes are an integral part of the financial statements.


                                      -3-
<PAGE>


                                                                  GENELINK, INC.
                                                        STATEMENTS OF OPERATIONS
                                                                     (UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,                              2002              2001
                                                       ------------    ------------
<S>                                                    <C>             <C>
REVENUE                                                $      5,848    $      5,794
                                                       ------------    ------------
COSTS OF GOODS SOLD                                             903             609
                                                       ------------    ------------
GROSS PROFIT                                                  4,945           5,185
                                                       ------------    ------------
EXPENSES

         Selling, general & administrative                  305,841         307,218
         Consulting                                          41,406          18,970
         Professional fees                                   22,788          49,651
         Advertising & promotion                             24,025           9,609
         Amortization & depreciation                          1,990           1,006
                                                       ------------    ------------
                                                            396,050         386,454
                                                       ------------    ------------
INTEREST EXPENSE                                                  0          12,163
                                                       ------------    ------------
NET LOSS BEFORE EXTRAORDINARY ITEM                         (391,105)       (393,432)

EXTRAORDINARY ITEM-FORGIVENESS OF DEBT                            0          14,010
                                                       ------------    ------------
NET LOSS BEFORE PROVISION FOR INCOME TAXES                 (391,105)       (379,422)

PROVISION FOR INCOME TAXES                                        0               0
                                                       ------------    ------------
NET LOSS                                               $   (391,105)   $   (379,422)
                                                       ------------    ------------
NET LOSS PER SHARE, BASIC & DILUTED                    $      (0.02)   $      (0.03)
                                                       ------------    ------------
         Weighted average common shares and diluted
         Potential common shares                         16,945,946      12,982,151
                                                       ============    ============
</TABLE>


    The accompanying notes are an integral part of the financial statements.


                                      -4-
<PAGE>


                                                                  GENELINK, INC.
                                                        STATEMENTS OF CASH FLOWS
                                                                     (UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,                                 2002           2001
                                                            ---------    ---------
<S>                                                         <C>          <C>
CASH FLOWS FROM OPERATING ACTIVITIES
  Net loss                                                  $(391,105)   $(379,422)
  Adjustments to reconcile net loss to net cash used in
    operating activities
    Depreciation and amortization                               1,990        1,006
    Amortization of bond discount                                   0       32,119
    Fair value of compensation related to vested options      200,000      200,000
    Common stock issued for services                           24,840       19,689
    Fair value of options granted for consulting services      55,430            0
    Changes in operating assets and liabilities
                  Accounts receivable                          (2,523)       2,258
                  Inventory                                       723          130
                  Prepaid expenses                            (10,385)      (7,250)
                  Accounts payable & accrued expenses          35,270       41,091
                  Accrued payroll taxes                        (9,680)       3,474
                  Accrued interest                                  0        8,912
                  Accrued compensation                         65,718       42,543
                                                            ---------    ---------
Net cash used in operating activities                         (29,722)     (35,450)
                                                            ---------    ---------
CASH FLOWS FROM INVESTING ACTIVITIES
  Capital expenditures                                         (3,429)           0
  Increase in subscriptions receivable                        (66,500)           0
                                                            ---------    ---------
Net cash used in investing activities                         (69,929)           0
                                                            ---------    ---------
CASH FLOWS FROM FINANCING ACTIVITIES
  Repayments of loans payable                                       0      (12,730)
  Proceeds relating to issuance of common stock (net)         252,750       35,000
                                                            ---------    ---------
Net cash provided by financing activities                   $ 252,750    $  22,270
                                                            ---------    ---------
</TABLE>

    The accompanying notes are an integral part of the financial statements.


                                      -5-
<PAGE>


                                                                  GENELINK, INC.
                                                        STATEMENTS OF CASH FLOWS
                                                                     (UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,                       2002       2001
                                                 --------   --------
<S>                                              <C>        <C>
NET INCREASE (DECREASE) IN CASH AND
  CASH EQUIVALENTS                               $153,099   $(13,180)
                                                 --------   --------
Cash and cash equivalents, beginning of period    121,434     13,804
                                                 --------   --------
Cash and cash equivalents, end of period         $274,533   $    624
                                                 --------   --------
SUPPLEMENTARY CASH FLOW INFORMATION
  Income taxes paid                                     0          0
  Interest paid                                         0          0

NON-CASH FINANCING TRANSACTIONS:
  Accrued interest on subscriptions receivable     14,624     12,729
  Issuance of common stock for services            24,840     19,689
  Acquisition of treasury stock                    96,000          0
  Conversion of accounts payable to stock               0     30,000
</TABLE>

    The accompanying notes are an integral part of the financial statements.


                                      -6-
<PAGE>


                                                                  GENELINK, INC.
                                           NOTES TO INTERIM FINANCIAL STATEMENTS

         1 - DESCRIPTION OF
             ORGANIZATION

                                    BUSINESS ORGANIZATION

                                    Genelink, Inc. (the Company), operating in
                                    New Jersey, was organized under the laws of
                                    the Commonwealth of Pennsylvania to offer to
                                    the public the safe collection and
                                    preservation of a family's DNA material for
                                    later use by the family to determine genetic
                                    linkage. The Company is the successor by
                                    merger to a Delaware Corporation organized
                                    under the same name on September 21, 1994.
                                    The Company's executive offices are located
                                    in Margate, New Jersey.

                                    BUSINESS DESCRIPTION

                                    The Company was founded in response to the
                                    information being generated in the field of
                                    human molecular genetics. Management
                                    believes future generations could benefit
                                    from the DNA store of knowledge, as
                                    scientists are discovering an increasing
                                    number of connections between genes and
                                    specific diseases. For this reason, the
                                    Company has created a DNA banking service
                                    that stores DNA before and after an
                                    individual dies. This genetic history can
                                    help families determine if they are at risk
                                    for certain inherited diseases. DNA banking
                                    shifts the emphasis from diagnosis and
                                    treatment to detection and prevention.

                                    The Company has developed a patented DNA
                                    Collection Kit for the collection of DNA
                                    specimens of its clients. The DNA will be
                                    stored for 75-year intervals. Upon a
                                    client's request, and upon the payment of a
                                    retrieval fee, the stored DNA specimen can
                                    be retrieved and sent to a laboratory for
                                    testing.

                                    The Company has also developed three
                                    proprietary genetic indicator tests
                                    (Genelink's Genesis 1 Program) and has filed
                                    three patent applications. These tests are
                                    designed to measure genes that can
                                    contribute to disease and aging, predict an
                                    individual's risk for skin aging, and
                                    predict an individual's susceptibility to
                                    obesity. The Company's patented DNA
                                    Collection Kit will be used for the Program,
                                    which can assist nutritional companies and
                                    medical, health and anti-aging practitioners
                                    to offer a "more targeted" and improved
                                    approach to wellness/nutritional therapies.


                                      -7-
<PAGE>


                                                                  GENELINK, INC.
                                           NOTES TO INTERIM FINANCIAL STATEMENTS

         2 - BASIS OF
             PRESENTATION

                                    The accompanying unaudited financial
                                    statements have been prepared by the Company
                                    in accordance with the instructions to Form
                                    10-Q and Article 10 of Regulation S-X
                                    relating to interim financial statements.
                                    Accordingly, they do not include all of the
                                    information and footnotes required by
                                    generally accepted accounting principles for
                                    complete financial statements and should be
                                    read in conjunction with the financial
                                    statements and notes thereto included in the
                                    Annual Report on Form 10-K of Genelink, Inc.
                                    for the year ended December 31, 2001.

                                    In the opinion of management, all
                                    adjustments (consisting of normal recurring
                                    accruals) necessary to present fairly the
                                    information set forth in the accompanying
                                    financial statements have been included. The
                                    results reported in these financial
                                    statements for the three-month period ended
                                    March 31, 2002 should not be regarded as
                                    necessarily indicative of results that may
                                    be expected for the year ended December 31,
                                    2002.

         3 - INCOME TAXES

                                    At March 31, 2002, the Company had
                                    significant federal and state tax net
                                    operating loss carryforwards of
                                    approximately $6,075,000. The difference
                                    between the operating loss carryforwards on
                                    a tax basis and a book basis is due
                                    principally to differences in depreciation,
                                    amortization, and treatment of stock
                                    options. The federal carryforwards will
                                    begin to expire in 2009 and the state
                                    carryforwards will begin to expire in 2005.

                                    The Company had a net deferred tax asset of
                                    $735,000 at March 31, 2002, primarily from
                                    not operating loss carryforwards. A
                                    valuation allowance was recorded to reduce
                                    the net deferred tax asset to zero.


                                      -8-
<PAGE>


                                                                  GENELINK, INC.
                                           NOTES TO INTERIM FINANCIAL STATEMENTS


         4 - SHAREHOLDERS'
             EQUITY TRANSACTIONS

                          A.        COMMON STOCK

                                    During the three months ended March 31,
                                    2002, the Company issued 272,000 shares of
                                    common stock and 272,000 warrants to
                                    purchase common stock for cash consideration
                                    of $170,000. This is pursuant to the private
                                    placement offering from June, 2001 and
                                    subsequent amendments in 2001 and 2002.
                                    Using the Black-Scholes methodology, the
                                    warrants were valued at $108,240.

                                    The Company issued 400,000 shares of common
                                    stock for cash consideration of $135,000
                                    during the three months ended March 31,
                                    2002. The Company issued 36,000 shares of
                                    common stock for services rendered, valued
                                    at $24,840 for the three months ended March
                                    31, 2002.

                           B.       SUBSCRIPTION RECEIVABLE-OFFICERS

                                    During the three months ended March 31,
                                    2002, the Company advanced $66,500 to an
                                    officer. As of March 31, 2002 the loan and
                                    accrued interest was $1,001,313.

                           C.       STOCK OPTIONS AND WARRANTS

                                    With respect to stock options granted to
                                    officers of the Company in 1997, $200,000 of
                                    deferred compensation was amortized during
                                    the three months ended March 31, 2002.

                                    During the quarter ended March 31, 2002,
                                    $52,250 and $3,180 was charged against
                                    additional paid in capital and consulting
                                    fees, respectively, for options vested
                                    during the quarter that were issued in prior
                                    years pursuant to consulting agreements.

                           D.       TREASURY STOCK

                                    During the three months ended March 31,
                                    2002, 100,000 shares of common stock valued
                                    at $96,000 was returned to the Company and
                                    recorded as treasury stock. The stock was
                                    issued during 2001 for services rendered.


                                      -9-
<PAGE>


                                                                  GENELINK, INC.
                                           NOTES TO INTERIM FINANCIAL STATEMENTS


         5 - TRANSACTIONS
             WITH RELATED
             PARTIES

                                    Pursuant to consulting agreements with two
                                    officers, compensation of $65,718 was
                                    accrued during the quarter ended March 31,
                                    2002.

                                    SUBSEQUENT EVENT

                                    On April 24, 2002, the Company entered into
                                    a Distribution Agreement with NuGenix, LLC
                                    ("NuGenix"), pursuant to which it granted
                                    NuGenix the right to distribute vitamin and
                                    nutritional supplement products and regimens
                                    developed utilizing the Company's
                                    proprietary genetic profiling technology
                                    (the "Products") in the direct
                                    selling market with North America. The
                                    Distribution Agreement grants to NuGenix an
                                    exclusive right through January 31, 2003 and
                                    a non-exclusive right for a period of five
                                    years thereafter to market and sell the
                                    Products within North America through the
                                    direct selling market.

                                    In connection with entering into the
                                    Distribution Agreement, the Company has
                                    agreed to loan NuGenix $500,000 to fund
                                    NuGenix's operations, of which $180,000 was
                                    lent by the Company to NuGenix on April 24,
                                    2002. The loan is for a three year term,
                                    accrues interest at the rate of six percent
                                    (6%) per year and grants the Company the
                                    right to convert the principal balance of
                                    the loan into an equity position in NuGenix.
                                    To secure NuGenix's obligations with respect
                                    to the loan, NuGenix has granted the Company
                                    a first priority security interest in all of
                                    its assets and the members of NuGenix have
                                    pledged their membership interests in
                                    NuGenix to the Company. NuGenix is entirely
                                    owned by DePhillipo Family, LLC, which in
                                    turn is owned 100% 100% by the adult
                                    children of John R. DePhillipo, the Chief
                                    Executive Officer and President and a member
                                    of the Board of Directors of the Company.


                                      -10-
<PAGE>


ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
         RESULTS OF OPERATIONS

     Statements in this Report that relate to future results and events are
based on the Company's current expectations. Actual results in future periods
may differ materially from those currently expected or desired because of a
number of risks and uncertainties. For a discussion of factors affecting the
Company's business and prospects, see "Item 2 - Management's Discussion and
Analysis of Financial Condition and Results of Operations - Factors Affecting
the Company's Business and Prospects."

     Operating results for the three-month period ended March 31, 2002 are not
necessarily indicative of the results that may be expected for the full fiscal
year.

LIQUIDITY AND CAPITAL RESOURCES

     For the three-month period ended March 31, 2002, the Company's primary
liquidity requirements have been the implementation and funding of its sales and
marketing efforts, the payment of compensation to officers and other employees
and the payment of accounts payable. In the first three months of 2002, the
Company raised $305,000, primarily through the issuance of common stock and
warrants. Of this amount, $180,000 was loaned to NuGenix, LLC as further
described below.

     Cash and cash equivalents at March 31, 2002 amounted to $274,533 as
compared to $121,434 at December 31, 2001, an increase of $ 153,099, resulting
primarily from the raising of $305,000 through the issuance of common stock and
warrants. During the first three months of 2002, the Company's operating
activities utilized $29,722, as compared to $35,450 for the first three months
of 2001, a decrease of $5,728. Cash utilized during these periods resulted from
Company's net losses for such periods.

     Investing activities utilized $69,929 for the three months ended March 31,
2002 as compared to utilizing $0 for the three months ended March 31, 2001.
Financing activities provided $252,750 for the three month period ended March
31, 2002 as compared to $22,270 for the three months ended March 31, 2001.
Financing activities in the three months ended March 31, 2002 primarily resulted
from the issuance of common stock and warrants.

     The Company will require an additional $320,000 to fund its obligations to
NuGenix, LLC ("NuGenix"). On April 24, 2002, the Company entered into a
Distribution Agreement with NuGenix, pursuant to which it granted NuGenix the
right to distribute vitamin and nutritional supplement products and regimens
developed utilizing the Company's proprietary genetic profiling technology in
the direct selling market within North America. The Distribution Agreement
grants to NuGenix an exclusive right through January 31, 2003 and a
non-exclusive right for a period of five years thereafter to market and sell the
product within North America through the direct selling market. In connection
with entering into the Distribution Agreement,


                                      -11-
<PAGE>


the Company has agreed to loan NuGenix $500,000 to fund NuGenix's operations, of
which $180,000 was lent by the Company to NuGenix on April 24, 2002. The loan is
for a three year term, accrues interest at the rate of six percent per year and
grants the Company the right to convert the principal balance of the loan into
an equity position in NuGenix. To secure NuGenix's obligations with respect to
the loan, NuGenix has granted the Company a first priority security interest in
all of its assets and the members of NuGenix have pledged their membership
interests in NuGenix to the Company. NuGenix is entirely owned by the DePhillipo
Family, LLC which in turn is owned 100% by the adult children of John R.
DePhillipo, the Chief Executive Officer and President and a member of the Board
of Directors of the Company.

     The Company will require approximately $1,500,000 to implement its sales
and marketing strategy for the balance of 2002 and to fund its research and
development efforts for the balance of 2002. The Company has developed a
proprietary genetic test (the Program for Genetic Profiling of Oxidative
Stress((TM)), for which patents are pending) that provides a means of predicting
an individual's genetic capacity to combat oxidative stress. The Company's
patented DNA Collection Kit(R) will be used for the program, which can assist
nutritional companies and medical, health and anti-aging practitioners to offer
a more targeted and improved approach to wellness/nutritional therapies. The
Company intends to raise funds through a private placement of securities. Unless
the Company can increase its revenues and increase its stock price, it is
unlikely that the Company will be able to secure such financing. If the Company
is not able to secure such additional required capital, it will continue to
realize negative cash flow and losses and it is unlikely that it will be able to
continue operations.

RESULTS OF OPERATIONS

The following table sets forth certain operating information regarding the
Company:

<TABLE>
<CAPTION>
                               THREE MONTH      THREE MONTH
                               PERIOD ENDED    PERIOD ENDED
                              MARCH 31, 2002   MARCH 31, 2001
                               (UNAUDITED)      (UNAUDITED)

<S>                           <C>              <C>
Revenues                        $   5,848        $   5,794

Cost of Goods Sold              $     903        $     609


Net Earnings (Loss)             $(391,105)       $(379,422)

Net Earnings (Loss) Per Share   $   (0.02)       $    (.03)
</TABLE>


                                      -12-
<PAGE>



     The following summary table presents comp arative cash flows of the Company
for the three months ended March 31, 2002 and 2001.

<TABLE>
<CAPTION>
                                THREE MONTH      THREE MONTH
                                PERIOD ENDED     PERIOD ENDED
                               MARCH 31, 2002   MARCH 31, 2001

                               (UNAUDITED)        (UNAUDITED)
<S>                            <C>              <C>
Net cash used in operating
activities                      $ 29,722          $ 35,540
Net cash provided (used) by
investing activities            $ 69,929          $      0
Net cash provided by
financing activities            $252,750          $ 22,270
</TABLE>

      The Company had cash balances totaling $274,533 at March 31, 2002 and $624
at March 31, 2001.

COMPARISON OF THREE MONTHS ENDED MARCH 31, 2002 TO THREE MONTHS ENDED MARCH 31,
2001

FINANCIAL CONDITION

         Assets of the Company increased from $117,542 at March 31, 2001 to
$502,116 at March 31, 2002, an increase of $384,574. This increase was primarily
due to an increase in cash from $624 at March 31, 2001 to $274,533 at March 31,
2002, resulting from the $305,000 raised by the Company in the first three
months of 2002 through the sale of stock and warrants, and an increase in
prepaid expenses from $54,322 at March 31, 2001 to $133,263 at March 31, 2002.

         Liabilities decreased from $910,453 at March 31, 2001 to $607,525 at
March 31, 2002, a decrease of $302,928. This decrease was primarily due to a
reduction in notes payable from $480,000 at March 31,2001 to $0 at March 31,
2002, resulting from the conversion of notes payable into common stock in 2001,
as partially offset by an increase in accrued compensation from $214,861 at
March 31, 2001 to $423,525 at March 31, 2002.

CURRENT YEAR PERFORMANCE AND EARNINGS OUTLOOK

         Revenues. Total revenues for the three months ended March 31, 2002 were
$5,848 as compared to $5,794 for the three months ended March 31, 2001, an
increase of $ 54.

         Expenses. Total expenses for the three months ended March 31, 2002 were
$396,050 as compared to $398,617 for the three months ended March 31, 2001, a
decrease of $2,567, primarily resulting from a decrease in interest expense from
$12,163 for the three months ended


                                      -13-
<PAGE>


March 31, 2001 to $0 for the three months ended March 31, 2002, resulting from
the conversion of notes into common stock in 2001, as partially offset by
increase in consulting expenses from $18,970 for the three months ended March
31, 2001 to $41,406 for the three month ended March 31, 2002 and an increase in
advertising and promotional expenses from $9,609 for the three months ended
March 31, 2001 to $24,025 for the three months ended March 31, 2002, resulting
from increased advertising and promotions related to the Company's new genetic
profiling business.

         Losses. The Company incurred a loss of $391,105 for the three months
ended March 31, 2002 as compared to a loss of $393,432 prior to extraordinary
items for the three months ended March 31, 2001, a decrease of $2,327. This
decrease in the amount of losses incurred is primarily due to the $2,567
decrease in expenses for the three months ended March 31, 2002.

FACTORS AFFECTING THE COMPANY'S BUSINESS AND PROSPECTS

         There are a number of factors that affect the Company's business and
the result of its operations. These factors include general economic and
business conditions; the level of acceptance of the Company's products and
services; the rate and commercial applicability of advancements and discoveries
in the genetics field; and the Company's ability to enter into strategic
alliances with companies in the genetics, pharmaceutical and nutrition
industries; the ability of the Company to raise the financing necessary to fund
its business and marketing plan, fund its research and development to pay
salaries to its officers and employees and to pay its accounts payable.


                                      -14-
<PAGE>


         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                 GENELINK, INC.
                                  ------------
                                  (Registrant)

Date: May 14, 2002                      By: /s/ John R. DePhillipo
------------------                      --------------------------
                                           John R. DePhillipo, Chief Executive
                                              Officer and President


                                      -15-